Intranasal Stem Cell Secretome therapy to prevent COVID-19 complications
Acute respiratory distress syndrome (ARDS) is the key cause for the
morbidity and mortality due to COVID-19 infections. Recent clinical
evidences suggest chronic release of pro-inflammatory cytokines as a
prominent etiological factor. Adult stem cells are known to secrete
potent immunomodulatory and bioactive compounds. We propose a nebulizer
assisted treatment of Mesenchymal Stem Cells (MSCs) Secretome as a
therapy which will counterbalance the COVID-19 induced cytokine storm as
well as promote the regeneration of alveolar tissue attributed to the
intrinsic cytokines and growth factor present in the Secretome.
Intranasal administration of Secretome will not only protect against the
COVID-19 associated complications but also bring down the necessity of
the ventilator reducing the burden on health care infrastructure.